Veracyte, Inc.

309 articles with Veracyte, Inc.

• Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference

  4/2/2021

  Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 2:15 p.m. Eastern Time.

• Veracyte Appoints Muna Bhanji to Its Board of Directors

  3/22/2021

  Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately.

• Veracyte Completes Acquisition of Decipher Biosciences

  3/15/2021

  Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into 7 of the 10 most common cancers in the United States, while accelerating revenue growth.

• Veracyte Commends New USPSTF Lung Cancer Screening Guidelines

  3/10/2021

  Veracyte, Inc. (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening.

• Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference

  2/18/2021

  Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 3:40 p.m. Eastern Time.

• Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results

  2/17/2021

  Fourth Quarter Revenue Increased 16% to $34.5 Million; Volume Grew 14% to 13,130 Tests Decipher Acquisition to Expand Global Leadership in Cancer Genomic Diagnostics While Accelerating Growth Conference Call and Webcast Today at 4:30 p.m. ET

• Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

  2/11/2021

  Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, at 1:30 p.m. Eastern Time.

• Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021

  2/10/2021

  Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2020 after the close of market on Wednesday, February 17. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

• Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock

  2/5/2021

  Veracyte, Inc. announced the pricing of an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of $74.00 per share.

• Veracyte Announces Proposed Public Offering of Common Stock - Feb 03, 2021

  2/3/2021

  Veracyte, Inc. announced that it has commenced an underwritten public offering of $400.0 million in shares of its common stock.

• Veracyte to Acquire Decipher Biosciences

  2/3/2021

  Further solidifies global leadership in differentiated, genomics-driven cancer diagnostics Expands TAM with presence in 7 of the 10 most common cancers Expected to accelerate revenue growth

• Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results

  2/3/2021

  Veracyte, Inc . (Nasdaq: VCYT) today announced preliminary results for the fourth quarter and full year ended December 31, 2020. The company expects to report total revenue of between $34.0 million and $35.0 million and product and testing volume of between 13,000 and 13,200 tests for the fourth quarter ended December 31, 2020

• Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests

  12/16/2020

  Veracyte, Inc . (Nasdaq: VCYT) announced new preliminary performance data for its noninvasive nasal swab test for early lung cancer detection and its Percepta Genomic Atlas for informing treatment decisions at the time of diagnosis. Both tests are in development and scheduled to launch in

• Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson

  12/15/2020

  Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson1.

• Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020

  12/3/2020

  Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&D Day for investors and analysts on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST. The event will feature Veracyte senior management who will provide an overview of the company’s vision for transforming patient care in lung cancer, as well as leading pulmonologists who will discuss the chall

• Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/23/2020

  Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

• Veracyte Announces New General Manager Structure to Advance Global Expansion

  11/17/2020

  Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company’s growing roster of genomic tests and its global expansion. John Hanna, currently chief commercial officer, will become GM, endocrinology, breast cancer and lymphoma. The company

• Veracyte Announces Third Quarter 2020 Financial Results

  11/2/2020

  Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. For the third quarter of 2020, revenue was $31.1 million, compared to $20.7 million in the second quarter of 2020 and $31.0 million in the third quarter of 2019.

• Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier

  10/22/2020

  RNA sequencing and novel machine learning algorithms generate a test that improves lung cancer diagnosis using brushings from the main lung airway

• Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020

  10/19/2020

  Veracyte, Inc ., (Nasdaq: VCYT) today announced that new data presented at the CHEST Annual Meeting 2020 show that a genomic smoking index developed for use on samples obtained from the main lung airway can also be detected in nasal samples. The findings, shared in an oral presentation at the virtual meeting, reinforce the foundational “field of injury” technology behind Veracyte’s noninvasive nasal swab tes